Recent Updates — BTOG

Between September 30 and October 16, 2026, holders of Sangrix Inc.'s senior secured convertible notes converted an aggregate principal amount of $3,300,000 plus accrued interest of $209,807 into 2,153,257 Class A ordinary shares. The conversion occurred at a price of $1.63 per share. Sangrix Inc. operates in the biotechnology industry.

Sangrix Inc. filed an amended proxy statement proposing an 8-for-1 reverse share consolidation of its Class A and Class B ordinary shares to maintain Nasdaq listing compliance. The transaction would reduce authorized capital from 200 billion to 25 billion shares, with a new effective date of November 13, 2026. Sangrix Inc. is a biotechnology company.

Sangrix Inc. is soliciting shareholder approval for a proposed 10-for-1 reverse share consolidation of its Class A and Class B ordinary shares at an extraordinary general meeting on November 3, 2026. The transaction aims to increase the market price per share to satisfy Nasdaq’s $1.00 minimum bid price requirement and avoid immediate delisting. If approved, the consolidation will take effect on November 13, 2026, reducing authorized shares from 200 billion to 20 billion while maintaining the US$60 million total par value. The company also seeks approval to amend its memorandum and articles of association to reflect these changes. Sangrix Inc. operates in the artificial intelligence sector.

On October 21, 2026, Sangrix Inc. issued 75,000 Class B Ordinary Shares to Jinghai Jiang, its Chairman of the Board and Chief Executive Officer, at a price of $0.4390 per share for aggregate consideration of $32,925. The transaction was approved by the Board of Directors and the Audit Committee and completed pursuant to exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation S. Following the issuance, Jiang holds 100% of the outstanding Class B ordinary shares, representing approximately 35% of the total voting power of the company's issued and outstanding share capital. Sangrix Inc. operates in the biotechnology industry.

Sangrix Inc. filed an amendment to its Form 6-K to restate unaudited condensed consolidated financial statements for the six months ended December 31, 2025. The restatement corrects errors in classifying Class A Ordinary Shares with redemption rights as mezzanine equity, presenting interest expense on convertible debentures measured under the fair value option, and measuring deemed dividends from warrant down-round features. These adjustments are material to the previously issued statements but do not affect total assets, liabilities, or consolidated net loss. The filing also retroactively adjusts share counts for a 1-for-5 reverse split effective August 21, 2026, following a prior 1-for-60 split in January 2026. Sangrix Inc. operates in the cryptocurrency mining industry.